- Report
- May 2025
- 193 Pages
Global
From €3139EUR$3,545USD£2,718GBP
€3487EUR$3,939USD£3,020GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2469EUR$2,789USD£2,139GBP
- Report
- May 2025
- 183 Pages
Global
From €3139EUR$3,545USD£2,718GBP
€3487EUR$3,939USD£3,020GBP
- Report
- May 2025
- 200 Pages
Global
From €2205EUR$2,490USD£1,909GBP
- Report
- April 2025
- 200 Pages
Global
From €3975EUR$4,490USD£3,443GBP
- Report
- April 2025
- 200 Pages
Global
From €3975EUR$4,490USD£3,443GBP
- Report
- July 2025
- 196 Pages
Global
From €5179EUR$5,850USD£4,486GBP
- Report
- July 2025
- 381 Pages
Global
From €5179EUR$5,850USD£4,486GBP
- Report
- June 2025
- 400 Pages
Global
From €4382EUR$4,949USD£3,795GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2656EUR$3,000USD£2,300GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2469EUR$2,789USD£2,139GBP
- Report
- August 2024
- 150 Pages
Global
From €2469EUR$2,789USD£2,139GBP
- Report
- September 2024
- 117 Pages
Global
From €3984EUR$4,500USD£3,451GBP
- Report
- June 2025
- 89 Pages
North America
From €3054EUR$3,450USD£2,645GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3187EUR$3,600USD£2,760GBP
- Report
- December 2022
- 66 Pages
Global
From €3099EUR$3,500USD£2,684GBP
- Report
- August 2023
- 336 Pages
Global
From €4117EUR$4,650USD£3,566GBP
- Report
- July 2023
- 220 Pages
Global
From €1762EUR$1,990USD£1,526GBP
- Report
- May 2024
- 140 Pages
Global
From €5754EUR$6,499USD£4,983GBP
- Report
- June 2024
- 200 Pages
Global
From €7038EUR$7,950USD£6,096GBP

The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors.
Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more